Sutro Biopharma公告首批患者已在Phase 1试验中接受Stro-004给药,该药物是一种针对Tf表达实质肿瘤的下一代组织因子ADC。
Sutro Biopharma公告首批患者已在Phase 1试验中接受Stro-004给药,该药物是一种针对Tf表达实质肿瘤的下一代组织因子ADC。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.